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Obesity represents a growing health problem in the United 
States and worldwide, with a prevalence that has doubled 
since 1980 (1). In the United States, 70% of adults and 
37% of adolescents are overweight or obese. The chronic 
health implications of obesity make it a public health issue 
with significant economic ramifications. By promoting an 
altered whole-body physiology, obesity increases the risk for 
chronic diseases including diabetes, cardiovascular disease, 
and cancer (2).
To address the accelerating rate of obesity in the 
United States, the American Medical Association (AMA) 
House of Delegates took the stance of defining obesity 
as a disease state in 2013 (3,4). Recognizing obesity as a 
disease has the potential to improve access to treatment and 
stimulate the advancement of novel therapies. However, 
providing a disease label has other important consequences. 
Medicalizing obesity gives the status of “disease” to tens 
of millions of adults and children in the United States. It 
runs the risk of relying on costly medical treatment while 
neglecting preventive public policy measures to address the 
underlying societal determinants of obesity (5). Moreover, 
historically our classifications of health, disease, and obesity 
have been riddled with ambiguities.
Our perception of disease is shaped by sociocultural 
contexts and evolving health expectations, diagnostic 
capab i l i t i e s ,  and  soc ioeconomic  dr iv ing  forces . 
Osteoporosis, for example, had been previously considered 
an inevitable part of normal aging but was recognized as a 
disease by WHO in 1994 (6). By contrast, in the early 20th 
century, homosexuality was considered to be an endocrine 
disorder and later on an organic mental disorder before 
finally in 1974 becoming de-pathologized and removed 
from the Diagnostic and Statistical Manual IV. Obesity, on 
the other hand, is regarded as the product of an “obesogenic” 
environment consisting of commercially driven high 
caloric diets and reduced physical activity in the context of 
low health literacy and food deserts. The World Obesity 
Federation further defines obesity as a “chronic, relapsing, 
progressive, disease process” that requires intervention (3).
The lack of accurate metrics to classify obesity calls into 
question the utility of defining obesity as a disease in order 
to improve health outcomes. Efforts to define obesity are 
complicated by the imperfect measures available to classify 
the condition. The most widely accepted and established 
measure of obesity is the body mass index (BMI) scale, 
which was developed by Adolphe Quetelet in the late 
1800s (7).The BMI scale, however, suffers from important 
limitations including failure to account for variations in 
body composition; measurements tend to overestimate 
adiposity in athletes who have higher lean body mass and 
underestimate in the elderly who have diminished lean 
mass (8). Other less universal methods to measure body 
composition include waist circumference, waist to hip or 
height ratio, skin fold thickness, and dual energy X-ray 
absorptiometry. 
The challenges of classifying obesity using BMI are 
further illustrated by its nuanced role in cancer therapeutics 
and survival outcomes. Although obesity appears to promote 
tumorigenesis particularly in hormone receptor-positive 
breast cancer in post-menopausal women, high BMI also 
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has a protective role in other cancers—a phenomenon 
known as the “obesity paradox” (9-11). Such findings may 
be partly related to the deleterious effects of cachexia, but 
also suggest the need for tools beyond BMI to characterize 
the body habitus. In oncology, body composition analysis 
is a more accurate method of quantifying muscle mass and 
adiposity. Martin and colleagues found that BMI greater 
than 25 kg/m2 is associated with a survival advantage in 
GI and respiratory tract tumors, but this protective effect 
of obesity was eliminated in the presence of a low fat-free 
mass index, or sarcopenia (12). Sarcopenia visualized on CT 
imaging is significantly correlated with diminished overall 
survival across tumors of all stages due to greater rates of 
surgical complications, treatment toxicity, and markers of 
systemic inflammation (13). The nuanced role of obesity in 
oncology underscores the importance of accurately defining 
the body habitus to help guide tailored intervention in the 
era of precision medicine.
In a recent issue of Nature Medicine, Wang et al. [2019] 
demonstrated that checkpoint blockade with PD-1/PD-
L1 inhibitors harnesses the paradoxical effect of obesity in 
order to enhance tumor response to immunotherapy (14). 
While obesity promotes a meta-inflammatory state in which 
leptin is associated with increased PD-1 expression and T 
cell dysfunction, these features can be successfully targeted 
by PD-(L)1 checkpoint inhibition and therefore serve as a 
paradoxically positive prognostic factor. These findings are 
supported by other reports that link obesity with improved 
overall survival and progression-free survival in patients 
with metastatic melanoma, bladder cancer, colorectal 
cancer, lung cancer, and renal cell carcinoma treated with 
targeted or immunotherapy (15-21). Importantly, immune 
checkpoint blockade has achieved augmented survival 
outcomes for only a subset of patients, creating a critical 
need to identify predictive biomarkers to guide patient 
selection for treatment. New studies further indicate that 
the gut microbiome may also modulate cancer response 
to immune checkpoint inhibitor therapy and is an area of 
active research (22-26).
Obesity also impacts health in indirect ways. In radiology, 
for example, image quality and acquisition are compromised 
by the body habitus of an obese patient. The increased soft 
tissue mass in obesity diminishes the signal-to-noise ratio 
and complicates the radionuclide dosimetry calculations 
used in PET imaging (27). Since radionuclide dosimetry is 
dependent on weight (mCi/kg), obese patients who exceed 
the maximum allowed dose may require tailored scans using 
the highest field gamma cameras and imaging for longer 
durations in order to maximize counts.
The AMA decision to declare obesity as a disease is a 
well-intentioned effort to legitimize the condition and shift 
public discourse from blame and stigmatism to medical 
therapy. However, disease implies the need for costly 
treatment in the form of drugs, medical technologies, and 
bariatric surgery. To call obesity a disease is to furthermore 
ignore the limitations of obesity measurement tools that 
tremendously impact management and prognosis (5). 
Obesity may be better characterized as a multidimensional 
risk factor that requires social and policy reform as well 
as continued efforts to elucidate the components of the 
body habitus in order to inform preventive and therapeutic 
efforts, including those that harness the paradoxical effect 
of obesity to enhance immunotherapy response.
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